MediWound Future Growth
Future criteria checks 2/6
MediWound is forecast to grow earnings and revenue by 53.3% and 40.5% per annum respectively while EPS is expected to grow by 50.8% per annum.
Key information
53.3%
Earnings growth rate
50.8%
EPS growth rate
| Pharmaceuticals earnings growth | 21.2% |
| Revenue growth rate | 40.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 39 | -13 | N/A | N/A | 3 |
| 12/31/2025 | 27 | -22 | N/A | N/A | 4 |
| 12/31/2024 | 20 | -33 | N/A | N/A | 1 |
| 6/30/2024 | 20 | -20 | -22 | -14 | N/A |
| 3/31/2024 | 20 | -13 | -22 | -16 | N/A |
| 12/31/2023 | 19 | -7 | -17 | -10 | N/A |
| 9/30/2023 | 25 | -12 | -10 | -6 | N/A |
| 6/30/2023 | 26 | -14 | -10 | -7 | N/A |
| 3/31/2023 | 26 | -20 | -9 | -7 | N/A |
| 12/31/2022 | 26 | -20 | -12 | -12 | N/A |
| 9/30/2022 | 20 | -16 | -17 | -16 | N/A |
| 6/30/2022 | 21 | -15 | -15 | -14 | N/A |
| 3/31/2022 | 22 | -14 | -10 | -10 | N/A |
| 12/31/2021 | 24 | -14 | -9 | -9 | N/A |
| 9/30/2021 | 25 | -11 | -11 | -10 | N/A |
| 6/30/2021 | 25 | -10 | -7 | -6 | N/A |
| 3/31/2021 | 23 | -10 | -9 | -8 | N/A |
| 12/31/2020 | 22 | -9 | -8 | -7 | N/A |
| 9/30/2020 | 21 | -11 | -7 | -6 | N/A |
| 6/30/2020 | 19 | -12 | -12 | -12 | N/A |
| 3/31/2020 | 36 | 4 | 8 | 8 | N/A |
| 12/31/2019 | 32 | 2 | 7 | 8 | N/A |
| 9/30/2019 | 27 | 12 | 8 | 9 | N/A |
| 6/30/2019 | 23 | 12 | 11 | 12 | N/A |
| 3/31/2019 | 3 | -5 | -12 | -11 | N/A |
| 12/31/2018 | 3 | -6 | -13 | -12 | N/A |
| 9/30/2018 | 3 | -14 | -15 | -15 | N/A |
| 6/30/2018 | 3 | -14 | -17 | -16 | N/A |
| 3/31/2018 | 2 | -15 | N/A | -15 | N/A |
| 12/31/2017 | 2 | -15 | N/A | -16 | N/A |
| 9/30/2017 | 2 | -14 | N/A | -16 | N/A |
| 6/30/2017 | 2 | -16 | N/A | -18 | N/A |
| 3/31/2017 | 2 | -19 | N/A | -17 | N/A |
| 12/31/2016 | 2 | -19 | N/A | -16 | N/A |
| 9/30/2016 | 1 | -25 | N/A | -17 | N/A |
| 6/30/2016 | 1 | -23 | N/A | -18 | N/A |
| 3/31/2016 | 1 | -19 | N/A | -19 | N/A |
| 12/31/2015 | 1 | -22 | N/A | -20 | N/A |
| 9/30/2015 | 0 | -21 | N/A | -19 | N/A |
| 6/30/2015 | 0 | -22 | N/A | -18 | N/A |
| 3/31/2015 | 0 | -24 | N/A | -18 | N/A |
| 12/31/2014 | 0 | -19 | N/A | -16 | N/A |
| 9/30/2014 | 0 | -12 | N/A | -15 | N/A |
| 6/30/2014 | 0 | -10 | N/A | -13 | N/A |
| 3/31/2014 | 0 | -7 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: M8W is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: M8W is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: M8W is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: M8W's revenue (40.5% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: M8W's revenue (40.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if M8W's Return on Equity is forecast to be high in 3 years time